Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection
Michael Kaleko(Synthetic Biologics (United States)), Sheila Connelly(Synthetic Biologics (United States)), Nur A. Hasan(Universitas Nahdlatul Ulama Indonesia), John F. Kokai‐Kun(Synthetic Biologics (United States)), Joseph Sliman(Synthetic Biologics (United States)), Todd B. Parsley, Saul Tzipori(Tufts University), Perrti Koski, Poorani Subramanian(National Institute of Allergy and Infectious Diseases), Giovanni Widmer(New England Disabled Sports), Steven Hubert(Synthetic Biologics (United States)), J. Andrew Bristol(Synthetic Biologics (United States)), Annie Jones(Synthetic Biologics (United States))
Cited by 71
Related Papers
Longitudinal analysis of microbial interaction between humans and the indoor environment
|Science|2014|962
Evidence for the shikimate pathway in apicomplexan parasites
|Nature|1998|456
Comparative genomics reveals mechanism for short-term and long-term clonal transitions in pandemic <i>Vibrio cholerae</i>
|Proceedings of the National Academy of Sciences|2009|394
Comprehensive benchmarking and ensemble approaches for metagenomic classifiers
|Genome biology|2017|389
Temperature regulation of virulence factors in the pathogen <i>Vibrio coralliilyticus</i>
|The ISME Journal|2011|294